
ORIC Valuation
Oric Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
ORIC Relative Valuation
ORIC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORIC is overvalued; if below, it's undervalued.
Historical Valuation
Oric Pharmaceuticals Inc (ORIC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.76. The fair price of Oric Pharmaceuticals Inc (ORIC) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:9.90
Fair
-6.41
PE
1Y
3Y
5Y
Trailing
Forward
-3.56
EV/EBITDA
Oric Pharmaceuticals Inc. (ORIC) has a current EV/EBITDA of -3.56. The 5-year average EV/EBITDA is -3.36. The thresholds are as follows: Strongly Undervalued below -11.42, Undervalued between -11.42 and -7.39, Fairly Valued between 0.67 and -7.39, Overvalued between 0.67 and 4.70, and Strongly Overvalued above 4.70. The current Forward EV/EBITDA of -3.56 falls within the Historic Trend Line -Fairly Valued range.
-3.39
EV/EBIT
Oric Pharmaceuticals Inc. (ORIC) has a current EV/EBIT of -3.39. The 5-year average EV/EBIT is -3.19. The thresholds are as follows: Strongly Undervalued below -10.78, Undervalued between -10.78 and -6.99, Fairly Valued between 0.60 and -6.99, Overvalued between 0.60 and 4.39, and Strongly Overvalued above 4.39. The current Forward EV/EBIT of -3.39 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Oric Pharmaceuticals Inc. (ORIC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-7.42
P/OCF
Oric Pharmaceuticals Inc. (ORIC) has a current P/OCF of -7.42. The 5-year average P/OCF is -8.28. The thresholds are as follows: Strongly Undervalued below -21.10, Undervalued between -21.10 and -14.69, Fairly Valued between -1.86 and -14.69, Overvalued between -1.86 and 4.55, and Strongly Overvalued above 4.55. The current Forward P/OCF of -7.42 falls within the Historic Trend Line -Fairly Valued range.
-6.33
P/FCF
Oric Pharmaceuticals Inc. (ORIC) has a current P/FCF of -6.33. The 5-year average P/FCF is -7.79. The thresholds are as follows: Strongly Undervalued below -19.10, Undervalued between -19.10 and -13.44, Fairly Valued between -2.13 and -13.44, Overvalued between -2.13 and 3.53, and Strongly Overvalued above 3.53. The current Forward P/FCF of -6.33 falls within the Historic Trend Line -Fairly Valued range.
Oric Pharmaceuticals Inc (ORIC) has a current Price-to-Book (P/B) ratio of 2.33. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately 28.67% higher. Relative to its 5-year average P/B ratio of 2.12, the current P/B ratio is about 9.81% higher. Oric Pharmaceuticals Inc (ORIC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -24.91%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.95% , the current FCF yield is about -100.00% lower.
2.33
P/B
Median3y
1.81
Median5y
2.12
0.00
FCF Yield
Median3y
-24.91
Median5y
-20.95
Competitors Valuation Multiple
The average P/S ratio for ORIC's competitors is 665.42, providing a benchmark for relative valuation. Oric Pharmaceuticals Inc Corp (ORIC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ORIC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ORIC in the past 1 year is driven by Unknown.
People Also Watch

UFCS
United Fire Group Inc
30.540
USD
-0.39%

BYRN
Byrna Technologies Inc
19.400
USD
+1.15%

EZPW
EZCORP Inc
15.970
USD
-0.62%

MVST
Microvast Holdings Inc
2.650
USD
-3.28%

HIPO
Hippo Holdings Inc
31.620
USD
+2.66%

SVM
Silvercorp Metals Inc
4.590
USD
+0.22%

NEXN
Nexxen International Ltd
9.630
USD
+0.84%

ZIP
Ziprecruiter Inc
4.410
USD
+1.61%

GLAD
Gladstone Capital Corp
26.930
USD
-0.22%

EOLS
Evolus Inc
6.690
USD
-0.59%
FAQ

Is Oric Pharmaceuticals Inc (ORIC) currently overvalued or undervalued?
Oric Pharmaceuticals Inc (ORIC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.76. The fair price of Oric Pharmaceuticals Inc (ORIC) is between to according to relative valuation methord.

What is Oric Pharmaceuticals Inc (ORIC) fair value?

How does ORIC's valuation metrics compare to the industry average?

What is the current P/B ratio for Oric Pharmaceuticals Inc (ORIC) as of Aug 19 2025?

What is the current FCF Yield for Oric Pharmaceuticals Inc (ORIC) as of Aug 19 2025?

What is the current Forward P/E ratio for Oric Pharmaceuticals Inc (ORIC) as of Aug 19 2025?
